Activa el sistema linfático y favorece el drenaje de líquidos.

• Polyporus umbellatus sporophorum
• Extracto seco de centella (tit. 40% en asiaticósidos)
• Bromelina (tit. mín. 2400 GDU/g)
• Extracto seco de meliloto (tit. 20% en cumarinas)
• Cápsula de celulosa vegetal
• Polyporus umbellatus: hongo con acción diurética, especialmente útil en casos de retención
  de líquidos, edemas y dificultades para orinar. Estudios realizados han demostrado que el
  Polyporus no provoca efectos secundarios, ya que permite la eliminación de sodio y cloro,
  pero conserva el potasio. útil en casos de estasis linfática.
• Extracto seco de centella: mejora la circulación venosa estimulando los fibroblastos, células
  que regeneran el colágeno, sustancia fundamental para la salud de muchos tejidos del
  cuerpo. útil para mejorar situaciones de insuficiencia venosa periférica, calambres,
  hemorroides y celulitis.
• Bromelina extraída del tallo de la piña: acción proteolítica, antitrombótica, antiinflamatoria.
  útil para tratar inflamaciones leves de los tejidos blandos y en condiciones inflamatorias
  localizadas, especialmente en presencia de edema.
• Extracto seco de meliloto (tit. 20% en cumarinas): actúa sobre las paredes de las venas
  reduciendo su permeabilidad y aumentando la resistencia capilar. Mejora el retorno venoso y
  la circulación linfática, con actividad antiinflamatoria y antiedematosa. útil en presencia de
  hemorroides, várices, tromboflebitis y estasis linfática.

Tomar 2 cápsulas 2 veces al día, preferiblemente lejos de las comidas.

Envase de 90 cápsulas

SIN GLUTEN

NO OGM
Código producto laboratorio AVD340ES

Codice Paraf: A923582136

Codice EAN: 8059173430673

1. Yuan D, Mori J, Komatsu KI, Makino T, Kano Y. An anti-aldosteronic diuretic component (drain dampness) in Polyporus sclerotium. Biol Pharm Bull. 2004 27(6):867-70
2. The Pharmacological Pote ntial of Mushrooms Ulrike Lindequist, Timo H. J. Niedermeyer, and Wolf-Dieter Jülich. Evid. Based Complement. Altern. Med., Sep 2005; 2: 285 – 299
3. Bioactivity-directed isolation, identification of diuretic compounds from Polyporus umbellatus. Zhao Y.Y, Xie R.M, Chao X, Zhang Y, Lin RC, Sun W.J. J Ethnopharmacol.2009;126(1):184-7
4. Diuretic activity and kidney medulla AQP1, AQP2, AQP3, V(2)R expression of the aqueous extract of sclerotia ofsclerotia of Polyporus umbellatus FRIES in normal rats. Zhang G, Zeng X, Han L, Wei J.A, Huang H. J Ethnopharmacol. 2010 Epub
5. Incandela L, Cesarone MR, Cacchio M, De Sanctis MT, Santavenere C, D’Auro MG, Bucci M, Belcaro G.Total triterpenic fraction of Centella asiatica in chronic venous insufficiency and in high-perfusion microangiopathy. Angiology. 2001 Oct; 52 Suppl 2:S9-13)
6. (Cesarone MR, Laurora G, De Sanctis MT, Belcaro G. Activity of Centella asiatica in venous insufficiency. Minerva Cardioangiol 1992; 40: 137-43)
7. Cesarone MR, Laurora G, De Sanctis MT, Incandela L, Grimaldi R, Marelli C, Belcaro G. The microcirculatory activity of Centella asiatica in venous insufficiency. A double-blind study. Minerva Cardioangiol 1994; 42: 299-304)
8. Incandela L, Belcaro G, De Sanctis MT, Cesarone MR, Griffin M, Ippolito E, Bucci M, Cacchio M. Total triterpenic fraction of Centella asiatica in the treatment of venous hypertension: a clinical, prospective, randomized trial using a combined microcirculatory model. Angiology. 2001 Oct; 52 Suppl 2:S61-7)
9. Incandela L, Belcaro G, De Sanctis MT, Cesarone MR, Griffin M, Ippolito E, Bucci M, Cacchio M. Total triterpenic fraction of Centella asiatica in the treatment of venous hypertension: a clinical, prospective, randomized trial using a combined microcirculatory model. Angiology. 2001 Oct; 52 Suppl 2:S61-7). • Belcaro GV, Grimaldi R, Guidi G. Improvement of capillary permeability in patients with venous hypertension after treatment with TTFCA. Angiology 1990; 41: 533-40)
10. Arpaia MR, Ferrone R, Amitrano M, Nappo C, Leonardo G, del Guercio R. Effects of Centella asiatica extract on mucopolysaccharide metabolism insubjects with varicose veins. Int J Clin Pharmacol Res 1990; 10: 229-33)
11. Montecchio GP, Samaden A, Carbone S, Vigotti M, Siragusa S, Piovella F. Centella Asiatica Triterpenic Fraction (CATTF) reduces the number of circulating endothelial cells in subjects with post phlebitic syndrome. Haematologica 1991; 76: 256-9)
12. Kim YN, Park YS, Kim HK, Jeon BC, Youn SE, Lee HY. Enhancement of the attachment on microcarriers and tPA production by fibroblast cells in a serum-free medium by the addition of the extracts of Centella asiatica. Phytotechnology 1993; 13: 221-6)
13. Bonte F, Dumas M, Chaudagne C, Meybeck A. Influence of asiatic acid, madecassic acid, and asiaticoside on human collagen I synthesis. Planta Med 1994; 60: 133-5)
14. Maquart FX, Bellon G, Gillery P, Wegrowski Y, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by a triterpene extracted from Centella asiatica. Connect Tissue Res 1990; 24: 107-20). • Bonte F, Dumas M, Chaudagne C, Meybeck A. Comparativeactivity of asiaticoside and madecassoside on type I and III collagen synthesis by cultured human fibroblasts. Ann Pharm Fr 1995; 53: 38-42
15. Walker AF, Bundy R, Hicks SM, Middleton RW. Bromelain reduces mild acute knee pain and improves well-being in a dose-dependent fashion in an open study of otherwise healthy adults. Phytomedicine 2002;9:681-6
16. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update. J Ethnopharmacol 1988;22:191-203
17. Stone MB, Merrick MA, Ingersoll CD, et al. Preliminary comparison of bromelain and Ibuprofen for delayed onset muscle soreness management. Clin J Sport Med 2002;12:373-8. • Nettis E, Napoli G, Ferrannini A, Tursi A. IgE-mediated allergy to bromelain. Allergy 2001;56:257-8
18. Hale LP, Greer PK, Sempowski GD. Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clin Immunol 2002;104:183-90
19. Kane S, Goldberg MJ. Use of bromelain for mild ulcerative colitis. Ann Intern Med 2000;132:680. Klein G, Kullich W. Short-term treatment of painful osteoarthritis of the knee with oral enzymes. Clin Drug Invest 2000;19:15-23
20. Last JA. Hemorrhagic Sweet Clover Disease, Dicumarol, and Warfarin: the Work of Karl Paul Link. J. Biol. Chem. (2005) 280(8): e5 Kresge N, Simoni RD Hill RL. Hemorrhagic Sweet Clover Disease, Dicumarol, and Warfarin: the Work of Karl Paul Link. J. Biol. Chem. (2005) 280(8): e5
21. Campbell, H. A., and Link, K. P. Studies on the Hemorrhagic Sweet Clover Disease. IV. The Isolation and Crystallization of the Hemorrhagic Agent ( 1941) J. Biol. Chem. 138, 21–33) • Stahmann, M. A., Huebner, C. F., and Link, K. P. Studies on the Hemorrhagic Sweet Clover Disease. V. Identification and Synthesis of the Hemorrhagic Agent (1941) J. Biol. Chem. 138, 513-527)
22. Overman, R. S., Stahmann, M. A., Huebner, C. F., Sullivan, W. R., Spero, L., Doherty, D. G., Ikawa, M., Graf, L., Roseman, S.
23. Link, K. P. Studies on the Hemorrhagic Sweet Clover Disease. XIII. Anticoagulant Activity and Structure in the 4-Hydroxycoumarin Group (1944) J. Biol. Chem. 153, 5–24